Sandoz sells low-cost medicines, but tougher rules, fresh tariffs, and more lawsuits could make it harder to launch new products and keep prices from falling. See why some think its big bets on new factories and biosimilar launches may not be enough to protect profits as competition heats up.Read more
Sandoz is pushing more copycat versions of complex medicines and upgrading its own factories, which could lift profits as demand for lower-cost treatments grows worldwide. The big question is whether fierce price competition, reliance on partners, and uneven progress in the US end up squeezing those gains.Read more
Key Takeaways Rapid biosimilars adoption and manufacturing innovation are driving above-expected revenue growth, margin expansion, and sustainable profitability. Strong presence in emerging markets and expanding product pipeline enable diversified, resilient growth and long-term earnings acceleration.Read more
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
